While AI has revolutionised drug discovery and development in life sciences, its impact in commercialisation has been slower.

As the race to deliver personalised engagement at scale gains pace, artificial intelligence (AI) has become a critical ...

In Part 4 of our Life Sciences Industry Report, we turn our attention to advanced data analytics, wearable health devices, ...

A subsidiary of Sun Pharma has reached an agreement to buy the assets of Canada's Antibe Therapeutics, a developer of drugs ...

Meanwhile, Sage reported failed phase 2 trials of dalzanemdor in Alzheimer's, Parkinson's, and Huntington's disease, and ...

A trial exploring the use of a higher dose of Novo Nordisk's GLP-1 agonist semaglutide has shown that patients with obesity ...

The US regulator has cleared Lumakras (sotorasib) in combination with Amgen's anti-EGFR antibody Vectibix (panitumumab) for ...

That is the conclusion of a report by the global Commission on Clinical Obesity – published in The Lancet Diabetes and ...

At the top of that list, unsurprisingly, are Novo Nordisk obesity drugs Ozempic, Rybelsus, and Wegovy, all grouped together ...

Hospitals should expand and speed up testing of people hospitalised with influenza to see if they are suffering from bird flu ...

Generative artificial intelligence (GenAI) player Bioptimus has swelled its coffers with another financing round, raising $41 ...

While this subjective cognitive decline (SCD) linked to menopause tends to be transient, it can often occur at an age when ...